NCT04797910Unknown不适用
Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 24
- 主要终点
- HVPG changed and reached the response standard
研究概览
简要总结
Complications associated with portal hypertension are the leading cause of death in patients with cirrhosis. Until now, hepatic venous pressure gradient (HVPG) - the difference between the wedged hepatic venous pressure (WHVP) and the free hepatic vein pressure (FHVP)- has been the criterion standard to determine portal pressure. Antiviral therapy may decrease HVPG which needs to be verified.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with viral cirrhosis were diagnosed;
- •Age 18-80 years;
- •Need and willing to accept measure HVPG;
- •First HVPG measurement of more than 5 mmHg;
- •Signed Informed Consent
排除标准
- •Patients with viral cirrhosis have been treated with antiviral therapy and have achieved virological response;
- •Ready to accept or have accepted a TIPS procedure;
- •Splenic embolization was performed;
- •Inaccurate measurement of HVPG due to combined hepatic venous shunt;
- •Complicated with alcoholic liver disease, autoimmune liver disease or other types of liver disease;
- •Complicated with liver cancer or other organ malignancy;
- •Combined with severe cardiopulmonary disease affects survival;
- •Complicated with severe renal insufficiency;
- •Concomitant portal vein cavernous degeneration or extensive portal vein thrombosis;
- •Women who are planning to become pregnant or who are pregnant or breastfeeding.
结局指标
主要结局
HVPG changed and reached the response standard
时间窗: one year
HVPG response to therapy indicates a decrease in HVPG of at least 10% from baseline or to less than 12 mmHg after chronic treatment with NSBBs.
次要结局
- Antiviral therapy achieved a virological response(one year)
研究者
相似试验
进行中（未招募）
不适用
Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)Hepatitis DPortal HypertensionHepatitis BLiver CirrhosisNCT04863703Hannover Medical School11
招募中
不适用
The Effect of Monitoring PVP on Clinical Outcomes in Patients With PHPortal HypertensionNCT04820166Nanfang Hospital, Southern Medical University200
Unknown
不适用
HVPG-Guided Therapy vs Carvedilol Plus Endotherapy for the Prevention of Esophageal Variceal Rebleeding in Cirrhotic PatientsLiver CirrhosesVariceal HemorrhageEsophageal VaricesNCT04254822Air Force Military Medical University, China220
招募中
不适用
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)Polycythemia VeraNCT06506084FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS429
Unknown
4 期
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin ResistanceChronic Hepatitis CInsulin ResistanceNCT00370617University of Turin, Italy200